- Report
- October 2024
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 189 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- August 2024
- 142 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- March 2025
- 173 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- January 2025
- 250 Pages
Global
From €4752EUR$4,999USD£3,992GBP
- Report
- July 2024
- 200 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- November 2024
- 110 Pages
United States
From €5656EUR$5,950USD£4,752GBP
- Report
- December 2024
- 139 Pages
United States
From €2377EUR$2,500USD£1,997GBP
- Book
- March 2021
- 400 Pages
From €157EUR$165USD£132GBP
- Report
- November 2018
- 53 Pages
Global
From €8076EUR$8,495USD£6,784GBP
- Report
- July 2018
- 765 Pages
Global
From €20914EUR$22,000USD£17,570GBP
- Report
- June 2023
- 73 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Training
- 2 Hours
Global
€1922EUR$2,092USD£1,560GBP

Multiple Sclerosis (MS) is a chronic, progressive neurological disorder that affects the central nervous system. It is classified as an autoimmune disorder, meaning that the body's immune system mistakenly attacks healthy tissue. MS is a major area of research within the field of Allergy and Immunology, as it is believed that the immune system plays a role in the development and progression of the disease. Treatment options for MS include medications, physical therapy, and lifestyle modifications.
MS is a major health concern, with an estimated 2.3 million people living with the condition worldwide. Symptoms of MS can vary greatly from person to person, and can include fatigue, vision problems, muscle spasms, and difficulty with balance and coordination.
Companies in the MS market include Biogen, Novartis, Sanofi, Merck, and Teva Pharmaceuticals. Show Less Read more